Bronchiectasis
Conditions
Brief summary
The aim of this clinical trial is to assess the safety of: * single doses of the study drug CHF6333 in Healthy Volunteers (HVs) and in subjects with Bronchiectasis (BE) - Part I * repeated doses of the study drug CHF6333 in subjects with BE - Part II
Interventions
DRUGCHF6333
CHF6333 Part I SAD; CHF6333 Part II MD.
DRUGCHF6333 Placebo
Placebo Part I SAD; Placebo Part II MD.
Sponsors
Chiesi Farmaceutici S.p.A.
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Intervention model description
Part I: randomised, double-blind, placebo-controlled, single ascending dose, alternating cross-over design in HV and single dose in subjects with BE. Part II: randomised, double-blind, placebo-controlled, repeated-dose, 3-way cross-over design in subjects with BE.
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
Yes
Inclusion criteria
HV Inclusion Criteria: 1. Signed and dated informed consent obtained prior to any study-related procedure; 2. Healthy male or female subject ≥18 and ≤60 years of age at screening; 3. Ability to understand the study procedures and the risks involved, and to be trained to use inhalers correctly and to generate sufficient peak inspiratory flow (PIF) (at least 40 L/min) using the In-Check Dial set as per "GenuAir" inhaler resistance, at screening; 4. Body mass index (BMI) ≥18 and ≤35 kg/m2 at screening; 5. Non-smokers or ex-smokers who smoked \<5 pack-years and stopped smoking \>1 year prior to screening; 6. Good physical and mental status, determined via assessment of medical history and clinical examination, at screening and prior to randomisation; 7. Vital signs within normal limits at screening and prior to randomisation: diastolic blood pressure (DBP) ≥40 and ≤89 mmHg, and systolic blood pressure (SBP) ≥90 and ≤139 mmHg; body temperature \<37.5°C; 8. Triplicate 12-lead electrocardiogram (ECG) considered as normal (40 ≤ heart rate ≤110 bpm, 120 ms ≤ PR ≤210 ms, QRS ≤120 ms, Fridericia corrected QT interval \[QTcF\] ≤450 ms for males and QTcF ≤470 ms for females) at screening and prior to randomisation; 9. Lung function measurements within limits at screening and prior to randomisation: forced expiratory volume in 1 second (FEV1) \>80% predicted and FEV1/forced vital capacity (FVC) ratio \>0.70; 10. Male subjects willing to use a male condom throughout the study if they have women of childbearing potential (WOCBP) partners; male subjects with non-WOCBP partners or who are sterile do not have contraception requirements; 11. Female subjects (if WOCBP) and/or their partners (if fertile) must be willing to use a highly effective birth control method, preferably with low user dependency, throughout the study; female subjects who are non-WOCBP or who have non-fertile partners do not have contraception requirements. HV
Exclusion criteria
1. Participation in another clinical study where investigational drug was received and the last investigations were performed less than 3 months prior to randomisation; 2. Clinically relevant and uncontrolled respiratory, cardiac, hepatic, gastrointestinal, renal, endocrine, hematologic, metabolic, neurological, or psychiatric disorders that may interfere with successful completion of this protocol, according to the investigator's judgment; 3. Clinically relevant abnormal laboratory values at screening suggesting an unknown disease and requiring further clinical investigation or which may impact the safety of the subject or the evaluation of the results of the study, according to the investigator's judgment; 4. History of respiratory diseases; 5. Positive human immunodeficiency virus (HIV) 1 or HIV2 serology results at screening; 6. Hepatitis serology results which indicate acute or chronic hepatitis B (HB) or hepatitis C virus (HCV) at screening; 7. Documented coronavirus disease 2019 (COVID-19) diagnosis within 2 weeks prior to screening or prior to randomisation, or associated complications/symptoms, which have not resolved within 2 weeks prior to screening; 8. Blood donation or blood loss (equal or more than 450 mL) less than 2 months prior to screening or prior to randomisation; 9. Abnormal liver enzymes at screening or prior to randomisation (alanine aminotransferase \[ALT\] or aspartate aminotransferase \[AST\] or bilirubin: \>1.5× upper limit of normal \[ULN\]); 10. Positive urine test for cotinine at screening or prior to randomisation; 11. Documented history of alcohol abuse within 12 months prior to screening or a positive alcohol breath test at screening or prior to randomisation; 12. Documented history of drug abuse within 12 months prior to screening or a positive urine drug screen at screening or prior to randomisation; 13. Treatment with prohibited concomitant medications or if the subject is expected to take prohibited concomitant medications during the study; 14. Presence of any current infection, or previous infection that resolved less than 7 days prior to screening or prior to randomisation; 15. Known intolerance and/or hypersensitivity to any of the excipients contained in the formulation used in the study; 16. Unsuitable veins for repeated venepuncture; 17. Heavy caffeine drinker; 18. For females only: pregnant or lactating women, where pregnancy is defined as the state of a female after conception and until termination of the gestation, confirmed by a positive serum human chorionic gonadotropin laboratory test. A serum pregnancy test is to be performed at screening and a urine pregnancy test is to be performed prior to randomisation; 19. Use of any kind of electronic smoking devices within 6 months prior to screening. Part I BE subjects Inclusion Criteria: 1. Signed and dated informed consent obtained prior to any study-related procedure; 2. Male or female subject ≥18 and ≤80 years of age at screening; 3. Clinical history consistent with BE (cough, chronic sputum production, and/or recurrent respiratory infections) that is confirmed by chest computed tomography (CT) demonstrating BE affecting 1 or more lobes (confirmation may be based on prior chest CT); subjects whose past chest radiographic image records or report are not available will undergo chest CT scan during screening; 4. Post-bronchodilator FEV1 ≥50% of the predicted value at screening; 5. If currently receiving treatment for BE, this treatment should be administered at a stable dose; 6. Subjects in a stable clinical condition with no exacerbation of BE for at least 4 weeks prior to randomisation. A pulmonary exacerbation is defined as a deterioration in three or more of the key symptoms for at least 48 hours (cough, sputum volume and/or consistency, sputum purulence, breathlessness and/or exercise tolerance, fatigue and/or malaise, haemoptysis) AND a clinician-prescribed course of antibiotics; 7. Vital signs within normal limits at screening and prior to randomisation: DBP ≥40 and ≤89 mmHg, and SBP ≥90 and ≤150 mmHg; body temperature \<37.5°C; 8. Ability to understand the study procedures and the risks involved, and the ability to be trained to use the inhalers correctly and to generate sufficient PIF (at least 40 L/min) using the In-Check Dial set as per "GenuAir" inhaler resistance, at screening; 9. Male subjects willing to use a male condom throughout the study if they have WOCBP partners; male subjects with non-WOCBP partners or who are sterile do not have contraception requirements; 10. Female subjects (if WOCBP) and/or their partners (if fertile) must be willing to use a highly effective birth control method, preferably with low user dependency, throughout the study; female subjects who are non-WOCBP or who have non-fertile partners do not have contraception requirements. Part I BE subjects
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Safety and tolerability of single ascending doses of CHF6333 in HVs and a single dose in subjects with BE (Part I), and repeated doses in subjects with BE (Part II), in terms of AEs | Through study completion. Part I: an average of 12 weeks and 8 weeks respectively for HVs and BE subjects. Part II: an avarage of 26 weeks | — |
| Safety and tolerability of single ascending doses of CHF6333 in HVs and a single dose in subjects with BE (Part I), and repeated doses in subjects with BE (Part II), in terms of vital signs | Part I:screening, day(D)-1, D1(from pre-dose until 96hrs post-dose HV, 6hrs post-dose BE), 14 to 21D post-dose.Part II:screening, D-1, D1 and 27(from pre-dose until 6hrs post-dose), D28(from pre-dose until 2hrs post-dose), 14 to 21D after last dose | Arterial blood pressure (SBP and DBP) |
| heart rate (HR) | Part I: at day1 from pre-dose until 24hrs post-dose. Part II: at day1 and 27 from pre-dose until 8hrs post-dose | Safety and tolerability of single ascending doses of CHF6333 in HVs and a single dose in subjects with BE (Part I), and repeated doses in subjects with BE (Part II). |
| Safety and tolerability of single ascending doses of CHF6333 in HVs and a single dose in subjects with BE (Part I), and repeated doses in subjects with BE (Part II), in terms of 12-Lead ECG parameters from Holter: PR interval | Part I: at day1 from pre-dose until 24hrs post-dose. Part II: at day1 and 27 from pre-dose until 8hrs post-dose | Part I HVs only and Part II |
| Safety and tolerability of single ascending doses of CHF6333 in HVs and a single dose in subjects with BE (Part I), and repeated doses in subjects with BE (Part II), in terms of 12-Lead ECG parameters from Holter: QRS interval | Part I: at day1 from pre-dose until 24hrs post-dose. Part II: at day1 and 27 from pre-dose until 8hrs post-dose | Part I HVs only and Part II |
| Safety and tolerability of single ascending doses of CHF6333 in HVs and a single dose in subjects with BE (Part I), and repeated doses in subjects with BE (Part II), in terms of 12-Lead ECG parameters from Holter: Fridericia-corrected QT interval (QTcF) | Part I: at day1 from pre-dose until 24hrs post-dose. Part II: at day1 and 27 from pre-dose until 8hrs post-dose | Part I HVs only and Part II |
| Safety and tolerability of single ascending doses of CHF6333 in HVs and a single dose in subjects with BE (Part I), and repeated doses in subjects with BE (Part II), in terms of lung function parameters: FEV1 | Part I: screening, day-1, day1 (from pre-dose until 24hrs post-dose for HVs and 6hrs post-dose for BE. Part II: screening, day-1, day1 and 27 (from pre-dose until 6hrs post-dose), day 28 (from pre-dose until 2hrs post-dose | — |
| Safety and tolerability of single ascending doses of CHF6333 in HVs and a single dose in subjects with BE (Part I), and repeated doses in subjects with BE (Part II), in terms of lung function parameters: FVC | Part I: screening, day-1, day1 (from pre-dose until 24hrs post-dose for HVs and 6hrs post-dose for BE. Part II: screening, day-1, day1 and 27 (from pre-dose until 6hrs post-dose), day 28 (from pre-dose until 2hrs post-dose | — |
| Safety and tolerability of single ascending doses of CHF6333 in HVs and a single dose in subjects with BE (Part I), and repeated doses in subjects with BE (Part II), in terms of lung function parameters: FEV1/FVC ratio | Part I: screening, day-1, day1 (from pre-dose until 24hrs post-dose for HVs and 6hrs post-dose for BE. Part II: screening, day-1, day1 and 27 (from pre-dose until 6hrs post-dose), day 28 (from pre-dose until 2hrs post-dose | — |
| Safety and tolerability of single ascending doses of CHF6333 in HVs and a single dose in subjects with BE (Part I), and repeated doses in subjects with BE (Part II), in terms of lung function parameters: FEV1 percentage of predicted | Part I: screening, day-1, day1 (from pre-dose until 24hrs post-dose for HVs and 6hrs post-dose for BE. Part II: screening, day-1, day1 and 27 (from pre-dose until 6hrs post-dose), day 28 (from pre-dose until 2hrs post-dose | — |
| Number of participants with clinical laboratory tests: Haematology | Part I: screening, day-1 and day5 (pre-dose) for HVs/FU for BE. Part II: screening, day-1 and 27 (pre-dose) | Safety and tolerability of single ascending doses of CHF6333 in HVs and a single dose in subjects with BE (Part I), and repeated doses in subjects with BE (Part II), in terms of clinical laboratory tests: Haematology |
| Number of participants with clinical laboratory tests: Biochemistry | Part I: screening, day-1 and day5 (pre-dose) for HVs/FU for BE. Part II: screening, day-1 and 27 (pre-dose) | Safety and tolerability of single ascending doses of CHF6333 in HVs and a single dose in subjects with BE (Part I), and repeated doses in subjects with BE (Part II), in terms of clinical laboratory tests: Biochemistry |
| Number of participants with clinical laboratory tests: Urinalysis | Part I: screening, day-1 and day 5 (pre-dose) for HVs/FU for BE. Part II: screening, day-1 and 27 (pre-dose) | Safety and tolerability of single ascending doses of CHF6333 in HVs and a single dose in subjects with BE (Part I), and repeated doses in subjects with BE (Part II), in terms of clinical laboratory tests: Urinalysis |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Pharmacokinetic variables in plasma in HVs only (Part I), in terms of Area Under the Curve | Day 1: from pre-dose until 96 hours post-dose | Area under the plasma concentration versus time curve (AUC) from Time 0 to 30 minutes post-dose (AUC0-30min), AUC from Time 0 to 12 hours post-dose (AUC0-12h), AUC from Time 0 to 24 hours post-dose (AUC0-24h), AUC from Time 0 to 96 hours post-dose (AUC0-96h), AUC from Time 0 to time of last quantifiable concentration (AUC0-t), AUC from Time 0 to infinity (AUC0-∞) |
| Pharmacokinetic variables in plasma in HVs only (Part I): Maximum concentration (Cmax) | Day1: from pre-dose until 96 hours post-dose | — |
| Pharmacokinetic variables in plasma in HVs only (Part I): Time to maximum concentration (tmax) | Day1: from pre-dose until 96 hours post-dose | — |
| Pharmacokinetic variables in plasma in HVs only (Part I): Terminal half-life (t½) | Day 1: from pre-dose until 96 hours post-dose | — |
| Pharmacokinetic variables in plasma in HVs only (Part I): Clearance (CL/F) | Day 1: from pre-dose until 96 hours post-dose | — |
| Pharmacokinetic variables in plasma in HVs only (Part I): Apparent volume of distribution during the terminal phase (Vz/F) | Day 1: from pre-dose until 96 hours post-dose | — |
| Pharmacokinetics variables in plasma in BE subjects (Part II); in terms of Area Under the Curve | At Day1 and 27: from pre-dose until 8 hours post-dose | Day1: AUC0-30min, AUC0-8h, AUC0-t \- Day27: AUC0-30min at steady state (AUC0-30min,ss), AUC0-8h at steady state (AUC0-8h,ss), AUC0-t at steady state (AUC0-t,ss) |
| Pharmacokinetics variables in plasma in BE subjects (Part II): Cmax | At Day1 and 27: from pre-dose until 8 hours post-dose | Day1: Cmax \- Day27: Cmax at steady state (Cmax,ss) |
| Pharmacokinetics variables in plasma in BE subjects (Part II): tmax | At Day 1 and 27: from pre-dose until 8 hours post-dose | Day 1: tmax \- Day27: tmax at steady state (tmax,ss) |
| Pharmacokinetics variables in plasma in BE subjects (Part II): Ratio of accumulation (Rac) for Cmax and AUC parameters | At Day 1 and 27: from pre-dose until 8 hours post-dose | — |
| CHF6333 plasma concentrations (Part II) | At Day 27 and 28: 3 hours post-dose | CHF6333 plasma concentrations on Day27 and 28 will be reported. |
Countries
United Kingdom
Contacts
CONTACTChiesi Clinical Trial info
PRINCIPAL_INVESTIGATORJames D. Chalmers
School of Medicine, University of Dundee, UK
Outcome results
None listed